Who are TIL + IL2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Licartin and CIK, IL-2 pre-treated CD19 cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/til-il2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

TIL + IL2 — Competitive Intelligence Brief

TIL + IL2 (TIL + IL2) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adoptive cell therapy; T cell immunotherapy. Area: Oncology.

phase 3 Adoptive cell therapy; T cell immunotherapy IL-2 receptor; tumor-associated antigens Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TIL + IL2 (TIL + IL2) — Nantes University Hospital. TIL + IL-2 combines tumor-infiltrating lymphocytes with interleukin-2 to expand and activate patient-derived T cells for adoptive cell therapy against cancer.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TIL + IL2 TARGET	TIL + IL2	Nantes University Hospital	phase 3	Adoptive cell therapy; T cell immunotherapy	IL-2 receptor; tumor-associated antigens
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adoptive cell therapy; T cell immunotherapy class)

Nantes University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TIL + IL2 — Competitive Intelligence Brief. https://druglandscape.com/ci/til-il2. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab